Antibody-Drug Conjugates – Page 5

BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront

1 year ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, biotech, China, Collaboration, Germany, MediLink, Solid Neoplasm, Technology Platform, TMALIN

BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany

Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates

1 year ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, hard-to-treat cancers, healthcare innovation, Pheon, Series B

Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.

AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing

1 year ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, Investments, Manufacture, production, Singapore

AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

1 year ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, expansion, Facility (object), Generalized, innovation, Investments, Singapore

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.

Bristol Myers-backed TORL Raises $158M to Advance Antibody-Drug Conjugates (ADCs) in Clinical Trials

1 year ago talkbio0Tagged Antibody-Drug Conjugates, bristol-myers, Clinical Trials, squibb, TORL

Bristol Myers Squibb, TORL, $158M funding, Antibody-Drug Conjugates (ADCs), Clinical Trials

Merck KGaA Partners with AI Techbio Caris Discovery for ADC Discovery, Up to $1.4 Billion in Milestones

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Artificial Intelligence, Caris Discovery, Discover, Merck KGaA, milestones

Merck KGaA, AI techbio, Caris Discovery, Antibody-Drug Conjugates (ADC), $1.4 billion milestones, ADC discovery deal

Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market

1 year ago talkbio0Tagged AbbVie's, Acquisition (action), Antibody-Drug Conjugates, competition, Elahere, FOLR1 gene, FOLR1 protein, human, Genmab, Midphase clinical trials, ProfoundBio, Rina-S, Rinatabart sesutecan

Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials